Resource impact summary report
The guidance is a rapid review of TA885 in which pembrolizumab plus chemotherapy with or without bevacizumab was recommended for use within the Cancer Drugs Fund (CDF).
Following rapid review, pembrolizumab plus chemotherapy with or without bevacizumab is recommended as an option for treating persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD-L1 with a combined positive score of at least 1. It is recommended only if:
- pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if the cancer progresses, and
- the company provides it according to the commercial arrangement.
Currently around 480 people per year are treated with pembrolizumab plus chemotherapy (with or without bevacizumab) in the CDF and this was expected to increase to around 620 if the treatment had remained in the CDF. After rapid review the use of pembrolizumab plus chemotherapy with or without bevacizumab in routine commissioning is expected to continue to increase until a steady state is reached, as shown in table 1 below.
Table 1 People expected to be treated with pembrolizumab plus chemotherapy
| Year | 2023/24 | 2024/25 | 2025/26 | 2026/27 | 2027/28 |
| Number of people treated with pembrolizumab plus chemotherapy | 480 | 620 | 620 | 620 | 620 |
There is an expected increase in use in 2024/25 which is line with the expected use in the CDF. The funding of the drug will move from the CDF to routine commissioning. As the number of people treated with pembrolizumab plus chemotherapy instead of chemotherapy alone increases, the number of annual administrations will also increase as pembrolizumab plus chemotherapy has a longer treatment duration. The increase in administrations is equivalent to around 4 per person treated on average.
This report is supported by a local template because pembrolizumab is available with a discount to the list price that is commercial in confidence. Users can enter the discounted price into the template to calculate the impact to routine commissioning of the drug moving out of the CDF.
Pembrolizumab plus chemotherapy is commissioned by NHS England, providers are NHS hospital trusts.
This page was last updated: